Browsing by Author "et al."
Now showing items 41-45 of 45
-
Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?
Piñero, Federico.; Rubinstein, Fernando.; Marciano, Sebastián.; Fernández, Nora.; Silva, Jorge.; Zambelo, Yanina.; Anders, Margarita.; et al. (Springer Science+Business Media, LLC, part of Springer Nature, 2019-03-01)Abstract Background: Biannual ultrasound (US) is recommended as the clinical screening tool for hepatocellular carcinoma (HCC). The effectiveness of surveillance according to the place where US is performed has not been ... -
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres, Vicente.; Chapman, Arlene.; Devuyst, Oliver.; Gansevoort, Ron.; Perrone, Ronald.; Koch, Gary.; Martin, Rodolfo.; et al. (Massachusetts Medical Society, 2017-11-16)BACKGROUND: In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed ... -
Transforming growth factor-β1 functional polymorphisms in myeloablative sibling hematopoietic stem cell transplantation
Berro, M.; Palau Nagore, M. V.; Rivas, M.; Longo, P.; Foncuberta, C.; Vitriú, A.; Remaggi, G.; et al. (Springer Nature [academic journals on nature.com], 2017-05-01)Hematopoietic stem cell transplantation (HSCT) with sibling donors (s.d.) is a life-saving intervention for patients with hematological malignancies. Numerous genetic factors have a role in transplant outcome. Several ... -
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Dominique, Germain.; Derralynn, Hughes.; Kathleen, Nicholls.; Daniel, Bichet.; Giugliani, Roberto.; Wilcox, William.; Amartino, Hernan.; et al. (Massachusetts Medical Society, 2016-08-11)BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms ... -
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero, Federico.; Mendizabal, Manuel.; Ridruejo, Ezequiel.; Herz, Fernando.; Ameigeiras, Beatriz.; Anders, Margarita.; Schinoni, María.; et al. (Wiley, 2019-01-13)Abstract Background & Aims: Data from Europe and North America have been published re‐ garding the risk of developing hepatocellular carcinoma (HCC) after treatment with direct antiviral agents (DAA). We proposed to ...